查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1434971

老年失智症藥物市場：按藥物類別、類型、分佈分類 - 2024-2030 年全球預測

Alzheimer's Therapeutics Market by Drug Class (Cholinesterase Inhibitors, NMDA [N-methyl-D-aspartate] Receptor Antagonist), Type (Medication, NMDA Receptor Antagonist), Distribution - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年老年失智症症藥物市場規模為61.4億美元，預計2024年將達66.6億美元，2030年將達109.6億美元，複合年成長率為8.63%。

老年失智症症藥物的全球市場

主要市場統計
基準年[2023] 61.4億美元
預測年份 [2024] 66.6億美元
預測年份 [2030] 109.6億美元
複合年成長率（%） 8.63%
阿茲海默症治療藥物Market-IMG1

FPNV定位矩陣

FPNV定位矩陣對於評估老年失智症藥物市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對老年失智症治療市場供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴見解，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。這種詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略，從而在市場上獲得競爭優勢。

該報告對以下幾個方面提供了寶貴的見解：

1-市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2-市場開拓：我們深入研究利潤豐厚的新興市場，並分析它們在成熟細分市場中的滲透率。

3- 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4-競爭力評估與資訊：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況、製造能力等進行全面評估。

5- 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1-老年失智症治療藥物市場的市場規模和預測是多少？

2-老年失智症症藥物市場預測期間需要考慮投資的產品、細分市場、應用和領域有哪些？

3-老年失智症藥物市場的技術趨勢和法律規範是什麼？

4-老年失智症症藥物市場主要供應商的市場佔有率是多少？

5-進入老年失智症藥物市場的合適型態和策略手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 人群中阿茲海默症的發生率增加
      • 擴大管道藥物開發和供應
      • 改善醫療設施和技術以早期發現阿茲海默症
    • 抑制因素
      • 資本集中阿茲海默症治療
    • 機會
      • 密集研發，包括雲端基礎的認知系統和人工智慧
      • 新生物標記和新再生療法的開發
    • 任務
      • 嚴格的醫藥品認證過程
  • 市場區隔分析
  • 市場趨勢分析
  • 高通膨的累積效應
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 法律規範

第6章依藥物類別分類的老年失智症症藥物市場

  • 膽鹼酯酶抑制劑
  • NMDA [N-甲基-D-天門冬胺酸]受體拮抗

第7章老年失智症症藥物市場：按類型

  • 藥品
    • 膽鹼酯酶抑制劑
    • 多奈哌齊
    • Galantamine
    • 卡巴拉汀
  • NMDA受體拮抗

第8章老年失智症症治療藥物市場分佈

  • 網路藥房
  • 零售藥房

第9章 北美和南美老年失智症症藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太阿茲海默老年失智症藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲的老年失智症症藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭形勢

  • FPNV定位矩陣
  • 市場佔有率分析：主要企業
  • 主要企業競爭情境分析
    • 新產品發布和功能增強

第13章競爭產品組合

  • 主要公司簡介
    • AbbVie Inc.
    • AC Immune SA
    • Acadia Pharmaceuticals Inc.
    • Alnylam Pharmaceuticals, Inc.
    • AlzeCure Pharma AB
    • Alzheon, Inc.
    • AstraZeneca PLC
    • Biogen Inc.
    • Cassava Sciences, Inc.
    • Cognition Therapeutics, Inc.
    • Corium, Inc.
    • Eisai Co., Ltd.
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd.
    • Grifols SA
    • H. Lundbeck A/S
    • Luye Pharma Group Ltd.
    • Merz Pharma GmbH & Co. KGaA
    • NeuroVision Imaging, Inc.
    • Novartis AG
    • Oryzon Genomics, SA
    • Pfizer, Inc.
    • Siemens Healthcare GmbH
    • Synaptogenix, Inc.
    • TauRx Pharmaceuticals Ltd.
    • VTV Therapeutics
  • 主要產品系列

第14章附錄

  • 討論指南
  • 關於許可證和定價
Product Code: MRR-A77F2EE7AAEF

[196 Pages Report] The Alzheimer's Therapeutics Market size was estimated at USD 6.14 billion in 2023 and expected to reach USD 6.66 billion in 2024, at a CAGR 8.63% to reach USD 10.96 billion by 2030.

Global Alzheimer's Therapeutics Market

KEY MARKET STATISTICS
Base Year [2023] USD 6.14 billion
Estimated Year [2024] USD 6.66 billion
Forecast Year [2030] USD 10.96 billion
CAGR (%) 8.63%
Alzheimer's Therapeutics Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Alzheimer's Therapeutics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Alzheimer's Therapeutics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Alzheimer's Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., AC Immune SA, Acadia Pharmaceuticals Inc., Alnylam Pharmaceuticals, Inc., AlzeCure Pharma AB, Alzheon, Inc., AstraZeneca PLC, Biogen Inc., Cassava Sciences, Inc., Cognition Therapeutics, Inc., Corium, Inc., Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Grifols S.A., H. Lundbeck A/S, Luye Pharma Group Ltd., Merz Pharma GmbH & Co. KGaA, NeuroVision Imaging, Inc., Novartis AG, Oryzon Genomics, S.A., Pfizer, Inc., Siemens Healthcare GmbH, Synaptogenix, Inc., TauRx Pharmaceuticals Ltd., and VTV Therapeutics.

Market Segmentation & Coverage

This research report categorizes the Alzheimer's Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Drug Class
    • Cholinesterase Inhibitors
    • NMDA [N-methyl-D-aspartate] Receptor Antagonist
  • Type
    • Medication
      • Cholinesterase inhibitors
      • Donepezil
      • Galantamine
      • Rivastigmine
    • NMDA Receptor Antagonist
  • Distribution
    • Online Pharmacies
    • Retail Pharmacies
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Alzheimer's Therapeutics Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Alzheimer's Therapeutics Market?

3. What are the technology trends and regulatory frameworks in the Alzheimer's Therapeutics Market?

4. What is the market share of the leading vendors in the Alzheimer's Therapeutics Market?

5. Which modes and strategic moves are suitable for entering the Alzheimer's Therapeutics Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Alzheimer's Therapeutics Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidences of Alzheimer's among population
      • 5.1.1.2. Growing development and availability of pipeline drugs
      • 5.1.1.3. Improved healthcare facilities and technologies for early detection of Alzheimer's
    • 5.1.2. Restraints
      • 5.1.2.1. Capital intensive treatment for Alzheimer's
    • 5.1.3. Opportunities
      • 5.1.3.1. Intense research and development with inclusion of cloud-based cognitive systems and artificial intelligence
      • 5.1.3.2. Development of novel biomarkers and emerging regenerative therapies
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent drug approval processes
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Alzheimer's Therapeutics Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Cholinesterase Inhibitors
  • 6.3. NMDA [N-methyl-D-aspartate] Receptor Antagonist

7. Alzheimer's Therapeutics Market, by Type

  • 7.1. Introduction
  • 7.2. Medication
    • 7.3.1. Cholinesterase inhibitors
    • 7.3.2. Donepezil
    • 7.3.3. Galantamine
    • 7.3.4. Rivastigmine
  • 7.3. NMDA Receptor Antagonist

8. Alzheimer's Therapeutics Market, by Distribution

  • 8.1. Introduction
  • 8.2. Online Pharmacies
  • 8.3. Retail Pharmacies

9. Americas Alzheimer's Therapeutics Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Alzheimer's Therapeutics Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Alzheimer's Therapeutics Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
  • 12.2. Market Share Analysis, By Key Player
  • 12.3. Competitive Scenario Analysis, By Key Player
    • 12.3.1. New Product Launch & Enhancement
      • 12.3.1.1. The Next Phase of Alzheimer's Therapeutics with Alzstatin ACD680
      • 12.3.1.2. Alzecure Selects CD and Enters Next Development Phase with Alzstatin ACD680 against Alzheimer's

13. Competitive Portfolio

  • 13.1. Key Company Profiles
    • 13.1.1. AbbVie Inc.
    • 13.1.2. AC Immune SA
    • 13.1.3. Acadia Pharmaceuticals Inc.
    • 13.1.4. Alnylam Pharmaceuticals, Inc.
    • 13.1.5. AlzeCure Pharma AB
    • 13.1.6. Alzheon, Inc.
    • 13.1.7. AstraZeneca PLC
    • 13.1.8. Biogen Inc.
    • 13.1.9. Cassava Sciences, Inc.
    • 13.1.10. Cognition Therapeutics, Inc.
    • 13.1.11. Corium, Inc.
    • 13.1.12. Eisai Co., Ltd.
    • 13.1.13. Eli Lilly and Company
    • 13.1.14. F. Hoffmann-La Roche Ltd.
    • 13.1.15. Grifols S.A.
    • 13.1.16. H. Lundbeck A/S
    • 13.1.17. Luye Pharma Group Ltd.
    • 13.1.18. Merz Pharma GmbH & Co. KGaA
    • 13.1.19. NeuroVision Imaging, Inc.
    • 13.1.20. Novartis AG
    • 13.1.21. Oryzon Genomics, S.A.
    • 13.1.22. Pfizer, Inc.
    • 13.1.23. Siemens Healthcare GmbH
    • 13.1.24. Synaptogenix, Inc.
    • 13.1.25. TauRx Pharmaceuticals Ltd.
    • 13.1.26. VTV Therapeutics
  • 13.2. Key Product Portfolio

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. ALZHEIMER'S THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. ALZHEIMER'S THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. ALZHEIMER'S THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. ALZHEIMER'S THERAPEUTICS MARKET DYNAMICS
  • FIGURE 7. ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 8. ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 10. ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
  • FIGURE 12. ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. ALZHEIMER'S THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 22. ALZHEIMER'S THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. ALZHEIMER'S THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. ALZHEIMER'S THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 6. ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY NMDA [N-METHYL-D-ASPARTATE] RECEPTOR ANTAGONIST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 9. ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 11. ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DONEPEZIL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY GALANTAMINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY RIVASTIGMINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY NMDA RECEPTOR ANTAGONIST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 17. ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 45. ASIA-PACIFIC ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 46. ASIA-PACIFIC ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 50. AUSTRALIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 51. AUSTRALIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. AUSTRALIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 54. CHINA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 55. CHINA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. CHINA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 58. INDIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 59. INDIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. INDIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 62. INDONESIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 63. INDONESIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. INDONESIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 66. JAPAN ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 67. JAPAN ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. JAPAN ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 70. MALAYSIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 71. MALAYSIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. MALAYSIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 74. PHILIPPINES ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 75. PHILIPPINES ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. PHILIPPINES ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 78. SINGAPORE ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 79. SINGAPORE ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. SINGAPORE ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 82. SOUTH KOREA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 83. SOUTH KOREA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. SOUTH KOREA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 86. TAIWAN ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 87. TAIWAN ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. TAIWAN ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 90. THAILAND ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 91. THAILAND ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. THAILAND ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 94. VIETNAM ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 95. VIETNAM ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. VIETNAM ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 103. DENMARK ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 104. DENMARK ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. DENMARK ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 107. EGYPT ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 108. EGYPT ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. EGYPT ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 111. FINLAND ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 112. FINLAND ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. FINLAND ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 115. FRANCE ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 116. FRANCE ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. FRANCE ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 119. GERMANY ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 120. GERMANY ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. GERMANY ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 123. ISRAEL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 124. ISRAEL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. ISRAEL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 127. ITALY ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 128. ITALY ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. ITALY ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 131. NETHERLANDS ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 132. NETHERLANDS ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. NETHERLANDS ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 135. NIGERIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 136. NIGERIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. NIGERIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 139. NORWAY ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 140. NORWAY ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. NORWAY ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 143. POLAND ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 144. POLAND ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. POLAND ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 147. QATAR ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 148. QATAR ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. QATAR ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 151. RUSSIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 152. RUSSIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. RUSSIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 155. SAUDI ARABIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 156. SAUDI ARABIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. SAUDI ARABIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 159. SOUTH AFRICA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 160. SOUTH AFRICA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. SOUTH AFRICA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 163. SPAIN ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 164. SPAIN ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. SPAIN ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 167. SWEDEN ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 168. SWEDEN ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. SWEDEN ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 171. SWITZERLAND ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 172. SWITZERLAND ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. SWITZERLAND ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 175. TURKEY ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 176. TURKEY ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. TURKEY ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 179. UNITED ARAB EMIRATES ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 180. UNITED ARAB EMIRATES ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. UNITED ARAB EMIRATES ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED KINGDOM ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED KINGDOM ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED KINGDOM ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 187. ALZHEIMER'S THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 188. ALZHEIMER'S THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 189. ALZHEIMER'S THERAPEUTICS MARKET LICENSE & PRICING